QGENF deals:
>>EAST HILLS, N.Y. and VENLO, Netherlands, Oct 29, 2001 /PRNewswire via COMTEX/ -- Pall Corporation (NYSE: PLL chart, msgs) and QIAGEN N.V. (Nasdaq: QGENF chart, msgs; Frankfurt, Neuer Markt: QIA, Easdaq:QGEN) today announced that they have entered into an agreement to jointly develop next-generation nucleic acid separation and purification products for certain applications in the life science market. The jointly developed products will exclusively be marketed by QIAGEN. This agreement puts Pall, the global leader in the highly sophisticated and broad filtration, separations and purification industry into an alliance with QIAGEN, the highly focused worldwide technology and market leader in the area of nucleic acid separation and purification products for the rapidly expanding life science market.
The first suite of products intended for near-term launch will focus on products combining certain of Pall's filtration technologies with certain of QIAGEN's technologies for applications in medium-, high-, and ultra-high throughput separation and purification of certain types of nucleic acids widely analyzed in genomics applications. The parties believe that these intended products which will also be optimized for use on QIAGEN's leading automation solutions will allow QIAGEN to further increase its expanding leadership in these market segments.
In addition, the Companies have also entered into a long-term supply agreement for certain of Pall's existing consumable products that QIAGEN expects to market to its customers once slight modifications to those products are completed. Financial terms were not disclosed.
"Pall's expertise in development of separations media and devices for the life sciences industry, combined with QIAGEN's leading nucleic acid separation and purification technologies forge a strong basis for a powerful alliance. Nucleic acid separation, purification and handling is believed to be an over $800 million market and possibly one of the fastest growing applications for separations technologies within the life science industry. We are very pleased to have been chosen by QIAGEN, the innovative global market and technology leader in this market as a partner," said Eric Krasnoff, Chairman and Chief Executive Officer of Pall Corporation.
Pall's filtration, separation and purification technologies accelerate the process of drug discovery and development and ensure drugs are produced to the highest standards. Pall is the only company whose portfolio of filtration, purification and separations technologies spans the full spectrum of life sciences applications from the earliest stages of research through production and delivery of new drugs and diagnostics for patient care. As part of the Company's Life Sciences mission, it is actively developing partnerships with companies, such as QIAGEN, that provide complementary technologies and that can thereby translate Pall's technologies into powerful product offerings for such partners' core markets. QIAGEN believes that certain of Pall's many separations technologies have potential applicability for nucleic acid separation and purification solutions.
Dr. Metin Colpan, Chief Executive Officer of QIAGEN added, "We are very pleased to be working with Pall on what we believe to be an exciting combination of Pall's broad and deep portfolio in separation technologies and media with QIAGEN's leadership and expertise in applying such technologies in nucleic acid separation and purification. QIAGEN has a history of expertise in modifying and enhancing separation and purification technologies directed and applied in other markets and integrating such technologies with technologies from QIAGEN's broad proprietary technology portfolio to create exciting nucleic acid separation and purification solutions for our customers. We have long admired Pall's fascinating breadth of technologies for purification of the most diverse substances in many different markets -- from water filtration to technologies for separations used in drug manufacturing. We believe that certain of Pall's technologies have the potential to show exciting applicability in nucleic acid separation and purification."<<
snip
>>VENLO, Netherlands and WARRINGTON, Pa., Oct 29, 2001 /PRNewswire via COMTEX/ -- QIAGEN N.V. (Nasdaq: QGENF chart, msgs; Neuer Markt: QIA; Easdaq:QGEN) and Polysciences, Inc. announced today that they have entered into a development, supply and marketing agreement. Under the terms of the agreement QIAGEN has received exclusive rights to develop and market certain of Polysciences' existing and future magnetic polymer technologies. QIAGEN believes that Polysciences' broad technology portfolio will lead to a range of products for manual and automated separation and purification of cells and proteins and that it will significantly expand QIAGEN's current magnetic particle technology range addressing certain applications in nucleic acid purification.
QIAGEN believes that the intended magnetic particle-based products uniquely combine requirements in the rapidly growing genomics, proteomics and cellomics markets. Certain forms of cell separation and protein separation required in cellomics and proteomics are closely linked with nucleic acid purification, in both research and clinical applications. Therefore, products which link the technologies will offer significant advantages for users in these markets, who will benefit all the more because the products will be optimized to share the same QIAGEN BioRobot automation platforms. Magnetic particles are seen by QIAGEN to have applicability in certain segments of nucleic acid purification and have therefore already been one of many technologies incorporated in the broad portfolio of QIAGEN nucleic acid purification products today.
QIAGEN intends to launch the first products resulting from this alliance in the second quarter of 2002. These intended first products will primarily address several applications in cell separation and will also include products for the separation and purification of nucleic acids and proteins. Under the terms of the agreement, Polysciences is to receive approximately $0.8 million in cash and approximately 52 thousands shares of restricted common stock in QIAGEN N.V. in exchange and in consideration for the transfer of certain assets.
"We are very impressed by the depth of polymer chemistry technology and expertise at Polysciences. This perfectly complements QIAGEN's technology focus," said Dr. Ulrich Schriek, QIAGEN's Vice President for Corporate Business Development. "The exclusive nature of this agreement allows QIAGEN to access Polysciences' substantial research and manufacturing strength with the goal of unleashing the benefits of magnetic polymers in applications requiring the moving or purifying biological samples using magnetic forces. We also look forward to working with Polysciences on research and development programs on new applications for our customer base. Their customers include many names in health care and other fields. With this alliance, we believe that Polysciences' technologies will soon be incorporated into a number of QIAGEN's market and technology leading products used in the handling, separation and purification of biomolecules."
"Polysciences looks forward to a mutually beneficial relationship in this specific particle area and other future endeavors with QIAGEN," said Mr. Michael Ott, CEO of Polysciences, Inc. "Polysciences brings its 40 years of experience in the specialty monomer, polymer, and particle areas together with Qiagen's extensive technical and marketing expertise in innovative biotechnology, to further help supply novel solutions to scientists around the world."
About QIAGEN N.V.
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,500 people worldwide. Further information on QIAGEN can be found at qiagen.com.
About Polysciences, Inc.
Polysciences Inc. is dedicated to addressing its leading chemistry competence to supplying products, services, and manufacturing. The Company's business can be segmented into three categories. The laboratory products category includes catalog sales of fine chemicals, certified & fluorescent dyes, electrophoresis reagents, histology & microscopy products, microspheres & particles, polymers & monomer, and other products for industrial users and scientists. In the areas of Custom Synthesis and Contract Manufacturing & Formulation, Polysciences offers the custom design of materials to suit specialized needs and an extensive array of FDA and GMP compliant manufacturing services. Operating out of facilities in Warrington, PA, and Eppelheim, Germany, privately held Polysciences, Inc. employs over 90 people, most of which are scientists. Further information can be found at polysciences.com.<<
snip
Cheers, Tuck |
